Skip to main content
. 2011 Aug 24;118(17):4567–4576. doi: 10.1182/blood-2011-05-355594

Table 2.

Hematologic response

Response Imatinib resistant
Imatinib intolerant
Total
No. % No. % No. %
Cumulative response
    Evaluable patients 199 88 287
    Complete response 172 86 75 85 247 86
Cumulative response among patients with no baseline complete hematologic response
    Evaluable patients 100 41 141
    Complete response 76 76 34 83 110 78
Reason for exclusion from analysis
    No baseline assessment 1 0 1